AG˹ٷ

STOCK TITAN

[8-K] SELECT MEDICAL HOLDINGS CORP Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Select Medical Holdings Corp. (NYSE: SEM) filed an 8-K to disclose board-approved amendments that completely restate the company’s bylaws, effective July 30 2025.

Key change: the revised bylaws tighten the advance-notice process for stockholder director nominations and other business in response to the SEC’s universal proxy rules (Rule 14a-19). A nominating stockholder must now:

  • State its intent to deliver a proxy statement and form of proxy to holders representing �67% of the voting power entitled to vote on director elections, and include all information required by Rule 14a-19.
  • Provide evidence that it has actually solicited proxies from holders of at least 67% of outstanding voting power.

The amended bylaws also make assorted clarifying and procedural updates to the company’s existing advance-notice provisions. The full text is filed as Exhibit 3.1.

No financial results, transactions, or earnings data are included in this report.

Select Medical Holdings Corp. (NYSE: SEM) ha presentato un modulo 8-K per comunicare le modifiche approvate dal consiglio di amministrazione che riscrivono completamente lo statuto della società, con efficacia dal 30 luglio 2025.

Modifica principale: il nuovo statuto rende più rigoroso il processo di preavviso per le candidature di amministratori da parte degli azionisti e per altre questioni, in risposta alle regole universali dei proxy della SEC (Regola 14a-19). Un azionista che propone una candidatura deve ora:

  • Dichiarare l’intenzione di consegnare una dichiarazione di procura e un modulo di procura ai detentori di azioni che rappresentano �67% del potere di voto avente diritto di votare nelle elezioni degli amministratori, includendo tutte le informazioni richieste dalla Regola 14a-19.
  • Fornire prova di aver effettivamente sollecitato procure da titolari che rappresentano almeno il 67% del potere di voto in circolazione.

Il nuovo statuto apporta inoltre chiarimenti e aggiornamenti procedurali alle disposizioni esistenti sul preavviso. Il testo completo è depositato come Allegato 3.1.

Questo rapporto non contiene dati finanziari, transazioni o risultati economici.

Select Medical Holdings Corp. (NYSE: SEM) presentó un formulario 8-K para divulgar enmiendas aprobadas por la junta que reescriben completamente los estatutos de la empresa, con vigencia a partir del 30 de julio de 2025.

Cambio clave: los estatutos revisados endurecen el proceso de aviso previo para las nominaciones de directores por parte de accionistas y otros asuntos, en respuesta a las reglas universales de poder de la SEC (Regla 14a-19). Un accionista nominado ahora debe:

  • Declarar su intención de entregar una declaración de poder y formulario de poder a los titulares que representen al menos el 67% del poder de voto con derecho a votar en las elecciones de directores, incluyendo toda la información requerida por la Regla 14a-19.
  • Proporcionar evidencia de que ha solicitado efectivamente poderes de al menos el 67% del poder de voto en circulación.

Los estatutos enmendados también realizan varias actualizaciones aclaratorias y procedimentales a las disposiciones existentes sobre aviso previo. El texto completo está presentado como Anexo 3.1.

Este informe no incluye resultados financieros, transacciones ni datos de ganancias.

Select Medical Holdings Corp. (NYSE: SEM)� 이사� 승인으로 회사� 정관� 완전� 재작성하� 수정안을 2025� 7� 30일부� 발효하는 내용� 8-K 보고서로 공시했습니다.

주요 변경사�: 수정� 정관은 SEC� 보편� 위임� 규칙(규칙 14a-19)� 대응하� 주주 이사 후보 지� � 기타 사안� 대� 사전 통지 절차� 강화했습니다. 지명하� 주주� 이제 다음� 해야 합니�:

  • 이사 선거� 투표� 권리가 있는 의결권의 67% 이상� 보유� 주주에게 위임� 설명� � 위임� 양식� 제공� 의사� 명시하고, 규칙 14a-19� 요구되는 모든 정보� 포함해야 합니�.
  • 실제� 발행� 의결권의 최소 67%� 해당하는 주주로부� 위임장을 실제� 요청했다� 증거� 제출해야 합니�.

수정� 정관은 기존� 사전 통지 조항� 대� 여러 명확� � 절차� 업데이트� 포함하고 있습니다. 전체 문서� 증빙서류 3.1� 제출되었습니�.

� 보고서에� 재무 실적, 거래 또는 수익 데이터가 포함되어 있지 않습니다.

Select Medical Holdings Corp. (NYSE: SEM) a déposé un formulaire 8-K pour divulguer des amendements approuvés par le conseil d'administration qui réécrivent complètement les statuts de la société, effectifs à partir du 30 juillet 2025.

Changement clé : les statuts révisés renforcent le processus de préavis pour les nominations d’administrateurs par les actionnaires et autres affaires, en réponse aux règles universelles de procuration de la SEC (Règle 14a-19). Un actionnaire proposant une nomination doit désormais :

  • Indiquer son intention de fournir une déclaration de procuration et un formulaire de procuration aux détenteurs représentant �67 % du pouvoir de vote habilités à voter lors des élections des administrateurs, et inclure toutes les informations requises par la Règle 14a-19.
  • Fournir la preuve qu’il a effectivement sollicité des procurations auprès des détenteurs représentant au moins 67 % du pouvoir de vote en circulation.

Les statuts amendés apportent également diverses mises à jour clarificatrices et procédurales aux dispositions existantes relatives au préavis. Le texte complet est déposé en Annexe 3.1.

Aucun résultat financier, transaction ou donnée de bénéfices n’est inclus dans ce rapport.

Select Medical Holdings Corp. (NYSE: SEM) hat einen 8-K-Bericht eingereicht, um vom Vorstand genehmigte Änderungen offenzulegen, die die Satzung des Unternehmens vollständig neu fassen und ab dem 30. Juli 2025 wirksam sind.

Wesentliche Änderung: Die überarbeitete Satzung verschärft den Vorankündigungsprozess für Aktionärsnominierungen von Direktoren und andere Angelegenheiten als Reaktion auf die universellen Proxy-Regeln der SEC (Regel 14a-19). Ein nominierender Aktionär muss nun:

  • Seine Absicht erklären, eine Proxy-Erklärung und ein Proxy-Formular an Inhaber zu übermitteln, die �67 % der Stimmrechte besitzen, die bei der Wahl der Direktoren stimmberechtigt sind, und alle von Regel 14a-19 geforderten Informationen einschließen.
  • Nachweisen, dass er tatsächlich Proxys von Inhabern von mindestens 67 % der ausstehenden Stimmrechte eingeholt hat.

Die geänderte Satzung enthält außerdem verschiedene Klarstellungen und Verfahrensaktualisierungen zu den bestehenden Vorankündigungsbestimmungen des Unternehmens. Der vollständige Text ist als Anlage 3.1 eingereicht.

Dieser Bericht enthält keine Finanzdaten, Transaktionen oder Gewinnangaben.

Positive
  • Provides clearer procedural roadmap for director nominations, potentially reducing litigation risk around proxy disputes.
Negative
  • High 67% solicitation requirement may impede shareholder ability to mount director challenges, weakening minority rights.

Insights

TL;DR: Bylaw overhaul raises solicitation threshold to 67%, likely discouraging activist challenges.

The new requirement forces any nominating shareholder to engage a super-majority of the voting base before its slate can be considered, substantially increasing cost and complexity for potential dissidents. While compliant with Rule 14a-19, the 67% threshold is well above the 50% standard many peers adopt, tilting governance power toward incumbent management. For long-term investors, reduced proxy contest risk may preserve strategic stability but could diminish external accountability. The change is governance-focused and has no direct balance-sheet impact, so market reaction should be limited. I classify the filing as impactful on governance, neutral on valuation.

Select Medical Holdings Corp. (NYSE: SEM) ha presentato un modulo 8-K per comunicare le modifiche approvate dal consiglio di amministrazione che riscrivono completamente lo statuto della società, con efficacia dal 30 luglio 2025.

Modifica principale: il nuovo statuto rende più rigoroso il processo di preavviso per le candidature di amministratori da parte degli azionisti e per altre questioni, in risposta alle regole universali dei proxy della SEC (Regola 14a-19). Un azionista che propone una candidatura deve ora:

  • Dichiarare l’intenzione di consegnare una dichiarazione di procura e un modulo di procura ai detentori di azioni che rappresentano �67% del potere di voto avente diritto di votare nelle elezioni degli amministratori, includendo tutte le informazioni richieste dalla Regola 14a-19.
  • Fornire prova di aver effettivamente sollecitato procure da titolari che rappresentano almeno il 67% del potere di voto in circolazione.

Il nuovo statuto apporta inoltre chiarimenti e aggiornamenti procedurali alle disposizioni esistenti sul preavviso. Il testo completo è depositato come Allegato 3.1.

Questo rapporto non contiene dati finanziari, transazioni o risultati economici.

Select Medical Holdings Corp. (NYSE: SEM) presentó un formulario 8-K para divulgar enmiendas aprobadas por la junta que reescriben completamente los estatutos de la empresa, con vigencia a partir del 30 de julio de 2025.

Cambio clave: los estatutos revisados endurecen el proceso de aviso previo para las nominaciones de directores por parte de accionistas y otros asuntos, en respuesta a las reglas universales de poder de la SEC (Regla 14a-19). Un accionista nominado ahora debe:

  • Declarar su intención de entregar una declaración de poder y formulario de poder a los titulares que representen al menos el 67% del poder de voto con derecho a votar en las elecciones de directores, incluyendo toda la información requerida por la Regla 14a-19.
  • Proporcionar evidencia de que ha solicitado efectivamente poderes de al menos el 67% del poder de voto en circulación.

Los estatutos enmendados también realizan varias actualizaciones aclaratorias y procedimentales a las disposiciones existentes sobre aviso previo. El texto completo está presentado como Anexo 3.1.

Este informe no incluye resultados financieros, transacciones ni datos de ganancias.

Select Medical Holdings Corp. (NYSE: SEM)� 이사� 승인으로 회사� 정관� 완전� 재작성하� 수정안을 2025� 7� 30일부� 발효하는 내용� 8-K 보고서로 공시했습니다.

주요 변경사�: 수정� 정관은 SEC� 보편� 위임� 규칙(규칙 14a-19)� 대응하� 주주 이사 후보 지� � 기타 사안� 대� 사전 통지 절차� 강화했습니다. 지명하� 주주� 이제 다음� 해야 합니�:

  • 이사 선거� 투표� 권리가 있는 의결권의 67% 이상� 보유� 주주에게 위임� 설명� � 위임� 양식� 제공� 의사� 명시하고, 규칙 14a-19� 요구되는 모든 정보� 포함해야 합니�.
  • 실제� 발행� 의결권의 최소 67%� 해당하는 주주로부� 위임장을 실제� 요청했다� 증거� 제출해야 합니�.

수정� 정관은 기존� 사전 통지 조항� 대� 여러 명확� � 절차� 업데이트� 포함하고 있습니다. 전체 문서� 증빙서류 3.1� 제출되었습니�.

� 보고서에� 재무 실적, 거래 또는 수익 데이터가 포함되어 있지 않습니다.

Select Medical Holdings Corp. (NYSE: SEM) a déposé un formulaire 8-K pour divulguer des amendements approuvés par le conseil d'administration qui réécrivent complètement les statuts de la société, effectifs à partir du 30 juillet 2025.

Changement clé : les statuts révisés renforcent le processus de préavis pour les nominations d’administrateurs par les actionnaires et autres affaires, en réponse aux règles universelles de procuration de la SEC (Règle 14a-19). Un actionnaire proposant une nomination doit désormais :

  • Indiquer son intention de fournir une déclaration de procuration et un formulaire de procuration aux détenteurs représentant �67 % du pouvoir de vote habilités à voter lors des élections des administrateurs, et inclure toutes les informations requises par la Règle 14a-19.
  • Fournir la preuve qu’il a effectivement sollicité des procurations auprès des détenteurs représentant au moins 67 % du pouvoir de vote en circulation.

Les statuts amendés apportent également diverses mises à jour clarificatrices et procédurales aux dispositions existantes relatives au préavis. Le texte complet est déposé en Annexe 3.1.

Aucun résultat financier, transaction ou donnée de bénéfices n’est inclus dans ce rapport.

Select Medical Holdings Corp. (NYSE: SEM) hat einen 8-K-Bericht eingereicht, um vom Vorstand genehmigte Änderungen offenzulegen, die die Satzung des Unternehmens vollständig neu fassen und ab dem 30. Juli 2025 wirksam sind.

Wesentliche Änderung: Die überarbeitete Satzung verschärft den Vorankündigungsprozess für Aktionärsnominierungen von Direktoren und andere Angelegenheiten als Reaktion auf die universellen Proxy-Regeln der SEC (Regel 14a-19). Ein nominierender Aktionär muss nun:

  • Seine Absicht erklären, eine Proxy-Erklärung und ein Proxy-Formular an Inhaber zu übermitteln, die �67 % der Stimmrechte besitzen, die bei der Wahl der Direktoren stimmberechtigt sind, und alle von Regel 14a-19 geforderten Informationen einschließen.
  • Nachweisen, dass er tatsächlich Proxys von Inhabern von mindestens 67 % der ausstehenden Stimmrechte eingeholt hat.

Die geänderte Satzung enthält außerdem verschiedene Klarstellungen und Verfahrensaktualisierungen zu den bestehenden Vorankündigungsbestimmungen des Unternehmens. Der vollständige Text ist als Anlage 3.1 eingereicht.

Dieser Bericht enthält keine Finanzdaten, Transaktionen oder Gewinnangaben.

false --12-31 0001320414 0001320414 2025-07-30 2025-07-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

 

FORM 8-K

 

current report

 

Pursuant to Section 13 or 15(d) of the

 

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 30, 2025

 

 

 

SELECT MEDICAL HOLDINGS CORPORATION

 

(Exact name of registrant as specified in its charter)

 

Delaware  001-34465  20-1764048
(State or other jurisdiction of
Incorporation)
  (Commission File
Number)
  (I.R.S. Employer
Identification No.)

 

 

 

4714 Gettysburg Road, P.O. Box 2034

Mechanicsburg, PA 17055

(Address of principal executive offices)  (Zip Code)

 

(717) 972-1100

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.001 per share SEM New York Stock Exchange (NYSE)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether either registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if either registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 5.03Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On July 30, 2025, the Board of Directors (the “Board”) of Select Medical Holdings Corporation (the “Company”) approved and adopted amendments to the Company’s bylaws, amending and restating them in their entirety (the “Amended and Restated Bylaws”).

 

The Amended and Restated Bylaws enhance and clarify certain procedural and disclosure requirements related to stockholder nominations of directors and submissions of proposals regarding other business at annual or special meetings of stockholders in light of the universal proxy rules adopted by the Securities and Exchange Commission pursuant to Rule 14a-19 under the Securities Exchange Act of 1934. Specifically, the Amended and Restated Bylaws provide, among other things, that the stockholder must (i) include in its advance notice of nomination, a representation that the stockholder intends to deliver a proxy statement and form of proxy to holders of the Company’s voting shares representing at least 67% of the voting power of the shares entitled to vote generally in the election of directors and all other information required under Rule 14a-19, and (ii) provide evidence that the stockholder has solicited proxies from holders of at least 67% of the voting power of the Company’s outstanding capital stock entitled to vote in the election of directors. In addition, the Amended and Restated Bylaws make certain other clarifying and procedural changes to the Company’s advanced notice bylaws.

 

The foregoing summary does not purport to be complete and is qualified in its entirety by reference to the text of the Amended and Restated Bylaws, which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

     (d) Exhibits.

 

Exhibit Number Description
   
3.1 Amended and Restated Bylaws of Select Medical Holdings Corporation.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  SELECT MEDICAL HOLDINGS CORPORATION
 
Date: August 4, 2025 By: /s/ Michael E. Tarvin
    Michael E. Tarvin
    Senior Executive Vice President, General Counsel and Secretary

 

 

 

 

 

FAQ

What did Select Medical (SEM) change in its bylaws?

The board adopted Amended and Restated Bylaws that tighten advance-notice rules and require proxy solicitation from holders of at least 67% voting power.

Why were the SEM bylaws amended in July 2025?

To align with the SEC’s universal proxy rules under Rule 14a-19 and to clarify nomination and proposal procedures.

Does the 8-K include any financial results for Select Medical?

No. The filing is limited to governance changes; it does not present revenues, earnings, or guidance.

When do the new SEM bylaw provisions take effect?

They became effective upon board approval on July 30 2025.

Where can investors read the full text of the amended bylaws?

The complete document is filed as Exhibit 3.1 to the 8-K and is incorporated by reference.
Select Medical

NYSE:SEM

SEM Rankings

SEM Latest News

SEM Latest SEC Filings

SEM Stock Data

1.61B
104.84M
14.95%
82.67%
2.53%
Medical Care Facilities
Services-hospitals
United States
MECHANICSBURG